$ELTX

Elicio Therapeutics (ELTX) reported Phase 2 trial results for camupepimut (ELI-002 7P) in pancreatic cancer, missing the primary DFS endpoint but showing favorable trends in subgroups. Key findings: 99% of patients showed immune responses, and DFS improvements were observed in ctDNA-negative (HR 0.51) and ctDNA-positive (HR 0.57) patients. The company plans to discuss Phase 3 study design with the FDA.

Elicio Therapeutics (ELTX) announced that new analyses from its Phase 2 AMPLIFY-7P study of ELI-002 7P in pancreatic cancer will be presented at ESMO Congress 2026. The findings aim to refine the Phase 3 development strategy, though the study did not meet its primary endpoint.

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an a

Elicio Therapeutics (Nasdaq: ELTX) said it closed a $15 million registered direct offering, selling 4,380,313 shares of common stock at gross proceeds of about $15 million. The company will use net proceeds to fund Phase 1 development of ELI-002 7P in metastatic PDAC, pipeline work, and general corporate purposes.

Elicio Therapeutics (NASDAQ:ELTX) shares fell 32.5% after it announced a $15M registered direct offering of 4,380,313 shares. The company plans to use net proceeds, plus existing cash, for Phase 1 development of ELI-002 7P in metastatic pancreatic cancer, pipeline, and working capital. Closure expected around July 6, 2026.

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 tm2619637d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 1, 2026, between Elicio Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified

Elicio Therapeutics (Nasdaq: ELTX) priced a $15 million registered direct offering to sell 4,380,313 shares of common stock, expected to close around July 6, 2026. Gross proceeds are about $15M before fees. Net proceeds will fund Phase 1 development of ELI-002 7P in metastatic PDAC and other pipeline/work capital.

uniQure (QURE) surged 78% after the FDA said the 3-year Phase I/II analysis for AMT-130 in Huntington’s could serve as primary evidence for an accelerated BLA; QURE plans to file in Q3 2026. Elicio (ELTX) rose 71% on Phase 2 AMPLIFY-7P responses. Lunai (LNAI) gained 40% on CEO updates; other biotech movers included CLPT, PLRZ and FTH.

Elicio Therapeutics (ELTX) reported post-hoc results from its Phase 2 AMPLIFY-7P trial of ELI-002 7P in resected mKRAS-driven pancreatic cancer. The study did not meet its primary DFS endpoint in the overall intent-to-treat population, which the company attributed partly to more R1 resections in the ELI-002 arm. In R0 patients (n=121), DFS improved (HR 0.65, p=0.048; median 23.8 vs 12.8 months). Elicio plans a refined Phase 3 focused on R0 patients and additional dosing, and said current cash su

Elicio Therapeutics reported a net loss of $39.6 million and an EPS of $(2.58) for the year ended December 31, 2025, an improvement from 2024. The company's operating loss was $37.7 million, and its cash reserves are projected to fund operations into Q3 2026. Key business highlights include clinical progress for ELI-002 7P in Phase 2, expansion of preclinical programs, and a strategic shift towards off-the-shelf immunotherapies.